Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Project details
Isreali cancer treatment company seeks investment
| Project region | Israel |
|---|---|
| Industry | Healthcare |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
Simon Laube
Assistant Manager, International Business Advisory
| Project highlights | NADAV technology - NDV - Mucus virus |
|---|---|
| Project description |
The Israeli cancer treatment company is developing a new biological / drug platform (NADAV technology) - a proprietary strain based on oncolytic virus NDV, which can target a variety of cancers. A series of in vivo, in vitro and clinical studies on NDV strains, show that NDV strains retain the potential selective and targeted cell death (apoptosis) mechanism of human cancer cells. Another virus named Mucus virus can preferentially replicate and kill cancer cells. For the virus to have oncolytic effect, it must be safe for human beings, only kill cancer cells while retaining normal cells, and genetic stability. The company seeks investment. |
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact UsOur Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
